Siglec14-TLR2 axis mediates anti-HIV-1 immunity in macrophages
- Int Immunopharmacol. 2025 Sep 24:166:115595. doi: 10.1016/j.intimp.2025.115595.
- 1. Guangxi Key Laboratory of AIDS Prevention and Treatment & School of Public Health, Guangxi Medical University, Nanning 530021, China.
- 2. Guangxi Key Laboratory of AIDS Prevention and Treatment & School of Public Health, Guangxi Medical University, Nanning 530021, China; Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-ASEAN, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China.
- 3. Guangxi Key Laboratory of AIDS Prevention and Treatment & School of Public Health, Guangxi Medical University, Nanning 530021, China; Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-ASEAN, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China. Electronic address: [email protected].
- 4. Guangxi Key Laboratory of AIDS Prevention and Treatment & School of Public Health, Guangxi Medical University, Nanning 530021, China; Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-ASEAN, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China. Electronic address: [email protected].
- 5. Guangxi Key Laboratory of AIDS Prevention and Treatment & School of Public Health, Guangxi Medical University, Nanning 530021, China; Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-ASEAN, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China. Electronic address: [email protected].
HIV-exposed seronegative (HESN) individuals exhibit natural resistance to HIV-1 Infection, providing a unique model to identify host factors that confer protection against the virus. Building upon our previous transcriptomic studies identifying Siglec14 as a key correlate of HIV-1 resistance in HESN individuals, we investigated its functional role in HIV-1 pathogenesis. We found that HIV-1 Infection upregulates Siglec14 in Macrophages, where it suppresses viral replication through potent Antiviral activity. Mechanistically, Siglec14 directly interacts with HIV-1 Nef protein and subsequently engages TLR2, triggering phosphorylation and activation of NF-κB p65 and IRF3. This dual signaling cascade initiates robust Antiviral responses via (1) NF-κB-mediated production of proinflammatory chemokines (CXCLs), and (2) IRF3-dependent induction of type I interferons (e.g., IFN-β) and interferon-stimulated genes (ISGs). Our results establish Siglec14 as a critical innate immune sensor that orchestrates Antiviral defenses through TLR2-mediated signaling, highlighting its potential as a therapeutic target for HIV immunotherapy and vaccine development.
-
Cat. No.Product NameCategory/Application